Danial Soltani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danial Soltani has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Mir Hosseini
Medical doctor, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication Aminreza Abkhoo
Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
1 shared publicationMazdak Jamshidi
1 shared publicationMina Naeini
Faculty of Medicine, Islamic Azad University of Najafabad, Isfahan, Iran
1 shared publication- Mohammad Mobin Mirimoghaddam
General physician, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication Mohammad Reza Rouhbakhsh Zahmatkesh
Department of Neurosurgery, Razavi Hospital, Mashhad, Iran
1 shared publication
Latest Publications
- 27 June 2026
- Published by InkVista Publishing House
- p. 57-71
Re-Irradiation and the Biology of Normal Tissue Recovery
Re-irradiation (re-RT)—delivering an additional course of radiotherapy to tissue previously exposed—forces radiation oncology to treat “normal tissue history” as a first-class planning variable. Unlike de novo irradiation, re-RT is applied to organs that may carry persistent, spatially heterogeneous injury (structural, vascular, inflammatory, and stem/progenitor compartment changes) that can modify both tolerance and the clinical phenotype of toxicity. Mod-ern consensus guidance emphasizes that re-RT is increasingly common, yet the radiobiology of recovery remains incompletely understood, motivating stand-ardized definitions and reporting so that dose–time–toxicity relationships can be learned with greater reliability. In parallel, technical and workflow advances are making re-RT more “computable”: historical dose can be mapped to new anatomy, converted into equieffective units (e.g., EQD2/BED), optionally time-corrected, and then used directly in treatment plan optimization and decision-making. This chapter integrates radiobiological concepts of tissue repair and memory with the practical challenges of cumulative dose modeling, organ-specific tolerance, modern planning techniques, and clinical decision algorithms—highlighting where current practice is robustly engineered but still biologically phenomenological.
- 27 June 2026
- Published by InkVista Publishing House
- p. 57-71
Re-Irradiation and the Biology of Normal Tissue Recovery
Re-irradiation (re-RT)—delivering an additional course of radiotherapy to tissue previously exposed—forces radiation oncology to treat “normal tissue history” as a first-class planning variable. Unlike de novo irradiation, re-RT is applied to organs that may carry persistent, spatially heterogeneous injury (structural, vascular, inflammatory, and stem/progenitor compartment changes) that can modify both tolerance and the clinical phenotype of toxicity. Mod-ern consensus guidance emphasizes that re-RT is increasingly common, yet the radiobiology of recovery remains incompletely understood, motivating stand-ardized definitions and reporting so that dose–time–toxicity relationships can be learned with greater reliability. In parallel, technical and workflow advances are making re-RT more “computable”: historical dose can be mapped to new anatomy, converted into equieffective units (e.g., EQD2/BED), optionally time-corrected, and then used directly in treatment plan optimization and decision-making. This chapter integrates radiobiological concepts of tissue repair and memory with the practical challenges of cumulative dose modeling, organ-specific tolerance, modern planning techniques, and clinical decision algorithms—highlighting where current practice is robustly engineered but still biologically phenomenological.
- Open Access
- 16 August 2025
- Published by National Academy of Sciences of Tajikistan in InfoScience Trends
- Vol. 2 (8) , 78-91
A Multimodal Deep Learning Framework Integrating CT Radiomics and Transcriptomics for Predicting Platinum Response in High-Grade Serous Ovarian Cancer
This study aimed to develop and evaluate a multimodal deep learning framework that integrates pre-treatment contrast-enhanced CT radiomics with tumor transcriptomics to predict platinum response in patients with high-grade serous ovarian cancer (HGSOC). A retrospective analysis was conducted using publicly available data from TCGA-OV and TCIA. The cohort included patients with baseline CT scans, bulk tumor RNA-seq, and clinical annotations for deriving platinum-free interval (PFI). A dual-tower neural network with attention-based fusion was designed to process radiomic features and RNA pathway activity scores. Model performance was rigorously assessed using nested cross-validation and compared against unimodal and clinical baselines. The multimodal fusion model achieved a mean ROC-AUC of [AUC_fusion] for predicting 6-month platinum resistance, outperforming radiomics-only (AUC_rad), transcriptomics-only (AUC_rna), and clinical-only (AUC_clin) models. The model demonstrated strong calibration, clinical utility on decision-curve analysis, and significant stratification of PFI in survival analysis. Performance remained robust across subgroup and sensitivity analyses. Integration of CT radiomics and transcriptomics using deep learning improves prediction of platinum response in HGSOC compared to single-modality approaches. This proof-of-concept study supports the potential of multimodal fusion, though external validation is required before clinical translation.
- 16 August 2025
- Published by National Academy of Sciences of Tajikistan in InfoScience Trends
- Vol. 2 (8) , 78-91
Open AccessA Multimodal Deep Learning Framework Integrating CT Radiomics and Transcriptomics for Predicting Platinum Response in High-Grade Serous Ovarian Cancer
This study aimed to develop and evaluate a multimodal deep learning framework that integrates pre-treatment contrast-enhanced CT radiomics with tumor transcriptomics to predict platinum response in patients with high-grade serous ovarian cancer (HGSOC). A retrospective analysis was conducted using publicly available data from TCGA-OV and TCIA. The cohort included patients with baseline CT scans, bulk tumor RNA-seq, and clinical annotations for deriving platinum-free interval (PFI). A dual-tower neural network with attention-based fusion was designed to process radiomic features and RNA pathway activity scores. Model performance was rigorously assessed using nested cross-validation and compared against unimodal and clinical baselines. The multimodal fusion model achieved a mean ROC-AUC of [AUC_fusion] for predicting 6-month platinum resistance, outperforming radiomics-only (AUC_rad), transcriptomics-only (AUC_rna), and clinical-only (AUC_clin) models. The model demonstrated strong calibration, clinical utility on decision-curve analysis, and significant stratification of PFI in survival analysis. Performance remained robust across subgroup and sensitivity analyses. Integration of CT radiomics and transcriptomics using deep learning improves prediction of platinum response in HGSOC compared to single-modality approaches. This proof-of-concept study supports the potential of multimodal fusion, though external validation is required before clinical translation.
- Open Access
- 25 December 2023
- Published by Rovedar in Journal of Lab Animal Research
- Vol. 2 (6) , 86-99
Advances in Nanotechnology for Enhanced Leukemia Therapy: A Systematic Review of In Vivo Studies
Background/Objective: Leukemia, a heterogeneous group of blood cancers, can present a significant clinical challenge due to its varying subtypes and complexity. The application of nanotechnology has the potential to revolutionize the treatment of leukemia. Based on in vivo studies, this systematic review provides an accurate and current assessment of nanotechnology therapeutic advances in leukemia treatment. Methods: The present systematic review focused on in vivo studies investigating nanotechnology's therapeutic potential for leukemia treatment. Comprehensive searches were conducted across leading databases, including PubMed, Scopus, and Google Scholar, to identify relevant publications. Selection criteria encompassed studies that employed animal models to assess nanotechnology effects on leukemia progression. Data extracted from selected articles were rigorously analyzed. This review included studies published between 2010 and 2022. Results: Based on the inclusion criteria, 24 relevant studies were identified. According to the findings of this review, nanotechnology has made substantial progress in the treatment of leukemia, as demonstrated by in vivo studies. Advanced nanoparticle-based drug delivery systems, precision gene therapies, and targeted therapeutic approaches have consistently exhibited superior outcomes in treating various leukemia subtypes in animal models. These compelling results emphasize the transformative potential of nanotechnology for leukemia therapy. Conclusion: In conclusion, the meticulous analyses of the in vivo studies underscore the role that nanotechnology plays in the advancement of the treatment of leukemia. Nanotechnology has demonstrated efficacy in preclinical models, indicating that it can be translated into clinical applications, offering new avenues for treating leukemia and reinforcing its position as an innovative therapeutic approach.
- 25 December 2023
- Published by Rovedar in Journal of Lab Animal Research
- Vol. 2 (6) , 86-99
Open AccessAdvances in Nanotechnology for Enhanced Leukemia Therapy: A Systematic Review of In Vivo Studies
Background/Objective: Leukemia, a heterogeneous group of blood cancers, can present a significant clinical challenge due to its varying subtypes and complexity. The application of nanotechnology has the potential to revolutionize the treatment of leukemia. Based on in vivo studies, this systematic review provides an accurate and current assessment of nanotechnology therapeutic advances in leukemia treatment. Methods: The present systematic review focused on in vivo studies investigating nanotechnology's therapeutic potential for leukemia treatment. Comprehensive searches were conducted across leading databases, including PubMed, Scopus, and Google Scholar, to identify relevant publications. Selection criteria encompassed studies that employed animal models to assess nanotechnology effects on leukemia progression. Data extracted from selected articles were rigorously analyzed. This review included studies published between 2010 and 2022. Results: Based on the inclusion criteria, 24 relevant studies were identified. According to the findings of this review, nanotechnology has made substantial progress in the treatment of leukemia, as demonstrated by in vivo studies. Advanced nanoparticle-based drug delivery systems, precision gene therapies, and targeted therapeutic approaches have consistently exhibited superior outcomes in treating various leukemia subtypes in animal models. These compelling results emphasize the transformative potential of nanotechnology for leukemia therapy. Conclusion: In conclusion, the meticulous analyses of the in vivo studies underscore the role that nanotechnology plays in the advancement of the treatment of leukemia. Nanotechnology has demonstrated efficacy in preclinical models, indicating that it can be translated into clinical applications, offering new avenues for treating leukemia and reinforcing its position as an innovative therapeutic approach.